150 related articles for article (PubMed ID: 35530345)
1. Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients.
Mariani S; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Donisi C; Persano M; Pinna G; Cimbro E; Parrino A; Spanu D; Pretta A; Lai E; Liscia N; Lupi A; Giglio E; Palomba G; Casula M; Pisano M; Palmieri G; Scartozzi M
Front Oncol; 2022; 12():852583. PubMed ID: 35530345
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
[TBL] [Abstract][Full Text] [Related]
3. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
[TBL] [Abstract][Full Text] [Related]
4. Skin Toxicity as Predictor of Survival in Refractory Patients with
Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Normanno N; Avallone A; Latiano T; Maiello E; Pietrantonio F; Cremolini C; Santabarbara G; Pinto C; Troiani T; Martinelli E; Ciardiello F; Martini G
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830870
[TBL] [Abstract][Full Text] [Related]
5. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
Ciardiello D; Napolitano S; Famiglietti V; Esposito L; De Falco V; Di Liello A; Avallone A; Maiello E; Pietrantonio F; Cremolini C; Zampino MG; Fazio N; Troiani T; Martinelli E; Ciardiello F; Martini G
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046778
[TBL] [Abstract][Full Text] [Related]
7. Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group.
Salgado Fernández M; Reboredo López M; Covela Rúa M; Candamio S; González-Villarroel P; Sánchez-Cousido LF; Graña B; Carral-Maseda A; Cameselle-García S; Varela Pose V; Gallardo-Martín ME; Martínez-Lago N;
Target Oncol; 2024 May; ():. PubMed ID: 38780742
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
Takahashi S; Ouchi K; Sakamoto Y; Mori T; Shimodaira H; Takahashi M; Ohori H; Kudo C; Takahashi Y; Imai H; Akiyama S; Takahashi M; Suto T; Murakawa Y; Oishi T; Isobe H; Okada Y; Kawai S; Yoshioka T; Sato T; Shindo Y; Sugiyama S; Komine K; Chiba N; Okita A; Yamaguchi T; Ishioka C
J Gastrointest Oncol; 2023 Apr; 14(2):676-691. PubMed ID: 37201044
[TBL] [Abstract][Full Text] [Related]
9. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
Vlachou MS; Mauri D; Zarkavelis G; Ntellas P; Tagkas C; Gkoura S; Pentheroudakis G
Exp Oncol; 2021 Sep; 43(3):252-256. PubMed ID: 34591420
[TBL] [Abstract][Full Text] [Related]
10. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
11. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with
Martini G; Ciardiello D; Napolitano S; Martinelli E; Troiani T; Latiano TP; Avallone A; Normanno N; Di Maio M; Maiello E; Ciardiello F
Front Oncol; 2023; 13():1069370. PubMed ID: 36860319
[TBL] [Abstract][Full Text] [Related]
13. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Moretto R; Rossini D; Capone I; Boccaccino A; Perrone F; Tamborini E; Masi G; Antoniotti C; Marmorino F; Conca V; Borelli B; Martignetti A; Pecora I; Simionato F; Cupini S; Ambrosini M; Manca P; Pietrantonio F; Falcone A; Cremolini C
Clin Colorectal Cancer; 2021 Dec; 20(4):314-317. PubMed ID: 34364814
[TBL] [Abstract][Full Text] [Related]
14. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
15.
Sunakawa Y; Nakamura M; Ishizaki M; Kataoka M; Satake H; Kitazono M; Yanagisawa H; Kawamoto Y; Kuramochi H; Ohori H; Nakamura M; Maeda F; Komeno C; Sonezaki T; Takeuchi M; Fujii M; Yoshino T; Tsuji A; Ichikawa W
JCO Precis Oncol; 2020 Nov; 4():898-911. PubMed ID: 35050760
[TBL] [Abstract][Full Text] [Related]
16. Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial.
Martinelli E; Ciardiello D; Martini G; Napolitano S; Del Tufo S; D'Ambrosio L; De Chiara M; Famiglietti V; Nacca V; Cardone C; Avallone A; Cremolini C; Pietrantonio F; Maiello E; Granata V; Troiani T; Cappabianca S; Ciardiello F; Nardone V; Reginelli A
Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38886336
[TBL] [Abstract][Full Text] [Related]
17. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis.
Schulz MS; Wolf S; Struck V; Thomas N; Husman G; Zeuzem S; Koch C; Trojan J; Schnitzbauer AA; Bechstein WO; Waidmann O
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406413
[TBL] [Abstract][Full Text] [Related]
20. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
